223 related articles for article (PubMed ID: 19523174)
1. Successful treatment of persistent pulmonary hypertension of the newborn with bosentan.
Nakwan N; Choksuchat D; Saksawad R; Thammachote P; Nakwan N
Acta Paediatr; 2009 Oct; 98(10):1683-5. PubMed ID: 19523174
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn.
Mohamed WA; Ismail M
J Perinatol; 2012 Aug; 32(8):608-13. PubMed ID: 22076415
[TBL] [Abstract][Full Text] [Related]
3. [Endothelin receptor antagonist bosentan. Breakthrough in the treatment of pulmonary hypertension].
MMW Fortschr Med; 2004 Dec; 146(50):72-3. PubMed ID: 15666438
[No Abstract] [Full Text] [Related]
4. Bosentan for the treatment of adult pulmonary hypertension.
Dwyer N; Kilpatrick D
Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
[TBL] [Abstract][Full Text] [Related]
5. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
[TBL] [Abstract][Full Text] [Related]
6. Bosentan.
Chin K; Channick R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
[TBL] [Abstract][Full Text] [Related]
7. Bosentan for chronic thromboembolic pulmonary hypertension.
Confalonieri M; Kodric M; Longo C; Vassallo FG
Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1503-12. PubMed ID: 19954311
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic microangiopathic nephropathy, pulmonary hypertension and nephromegaly: case report of a patient treated with endothelin receptor antagonist.
Losito A; Pittavini L; Covarelli C
Clin Nephrol; 2012 Feb; 77(2):164-70. PubMed ID: 22257549
[TBL] [Abstract][Full Text] [Related]
9. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
10. Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan.
Goissen C; Ghyselen L; Tourneux P; Krim G; Storme L; Bou P; Maingourd Y
Eur J Pediatr; 2008 Apr; 167(4):437-40. PubMed ID: 17701214
[TBL] [Abstract][Full Text] [Related]
11. Effect of bosentan therapy in persistent pulmonary hypertension of the newborn.
Maneenil G; Thatrimontrichai A; Janjindamai W; Dissaneevate S
Pediatr Neonatol; 2018 Feb; 59(1):58-64. PubMed ID: 28735030
[TBL] [Abstract][Full Text] [Related]
12. Weaning of epoprostenol in a small infant receiving concomitant bosentan for severe pulmonary arterial hypertension secondary to bronchopulmonary dysplasia.
Rugolotto S; Errico G; Beghini R; Ilic S; Richelli C; Padovani EM
Minerva Pediatr; 2006 Oct; 58(5):491-4. PubMed ID: 17008861
[TBL] [Abstract][Full Text] [Related]
13. [Bosentan].
Taéron C
Rev Infirm; 2005 Feb; (108):33-4. PubMed ID: 15816717
[No Abstract] [Full Text] [Related]
14. Bosentan.
Mathier MA; Ishizawar D
Expert Opin Pharmacother; 2010 Apr; 11(6):1023-34. PubMed ID: 20307226
[TBL] [Abstract][Full Text] [Related]
15. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation.
Hefke T; Zittermann A; Fuchs U; Schulte-Eistrup S; Gummert JF; Schulz U
Thorac Cardiovasc Surg; 2012 Feb; 60(1):26-34. PubMed ID: 21432755
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of portopulmonary hypertension with bosentan: case report.
Stähler G; von Hunnius P
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():62-6. PubMed ID: 16919013
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan.
Foley RJ; Metersky ML
Respiration; 2008; 75(2):211-4. PubMed ID: 16293957
[TBL] [Abstract][Full Text] [Related]
18. Funding linked to ongoing research: impact of the bosentan patient registry on pricing in Australia.
Wlodarczyk J; Reid CM; Pater G
Value Health; 2011; 14(6):961-3. PubMed ID: 21914519
[TBL] [Abstract][Full Text] [Related]
19. Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial.
Steinhorn RH; Fineman J; Kusic-Pajic A; Cornelisse P; Gehin M; Nowbakht P; Pierce CM; Beghetti M;
J Pediatr; 2016 Oct; 177():90-96.e3. PubMed ID: 27502103
[TBL] [Abstract][Full Text] [Related]
20. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
